ClinicalTrials.gg
Active, not recruitingNCT03329365Updated Sep 18, 2026

Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS

An observational study in Paroxysmal Nocturnal Hemoglobinuria, Embolic Stroke of Undetermined Source and Transient Ischemic Attack, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder, which can cause arterial or venous thrombosis. The frequency of PNH in young patients (\< 50 years old) with embolic stroke (ESUS), transient ischemic attack (ETUS) or superior sagittal sinus cerebral venous thrombosis (SSS-CVTUS) of undetermined source, is currently unknown. This study proposes to recruit ESUS, ETUS, SSS-CVTUS patients to determine the frequency of PNH diagnosis confirmed by flow cytometry in these patient populations.

Read the detailed description

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder leading to red blood cells hemolysis and thrombosis. PNH has been reported to be the cause of cerebral venous thrombosis and embolic ischemic strokes and is sometimes diagnosed after the ischemic event. In young patients with embolic ischemic stroke of undetermined source (ESUS), thrombophilia is usually investigated. However, access to PNH testing is limited. PNH is rarely investigated in stroke patients and its contribution to the pathophysiology of ESUS is unknown. The investigators hypothesize that this condition is underdiagnosed, resulting in potential preventive opportunities being lost, since PNH can be successfully treated.

This observational study aims to determine the frequency of PNH among young (≤50 years old) patients with recent ESUS or embolic transient ischemic attacks (TIA) of undetermined source (ETUS) and patients with SSS-CVT of undetermined source (SSS-CVTUS).

Patients with ESUS or ETUS will be first screened for: (a) evidence of hemolysis based on their plasma lactate dehydrogenase (LDH) levels, (b) unexplained anemia based on their hemoglobin (Hb) levels, and (c) unexplained cytopenia (e.g., neutropenia and thrombocytopenia). Flow cytometry analysis for PNH will be performed with blood samples collected from subjects with abnormal level of plasma LDH (1.5X ULN) or unexplained anemia or cytopenia.

Patients with SSS-CVTUS will undergo flow cytometry without prior screening.

In addition, plasma and DNA samples will be collected in an optional sub-study for future analysis of DNA mutations related to specific PNH phenotypes in patients with stroke.

02

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
  • Embolic Stroke of Undetermined Source
  • Transient Ischemic Attack
  • Cerebral Vein Thrombosis

Keywords

  • Flow cytometry
  • Lactate dehydrogenase (LDH) release
  • Anemia
  • Cytopenia
03

In context

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

This study's planned enrollment of 200 is above the median of 90 across 37 observational studies indexed under Hemoglobinuria, Paroxysmal.

Browse Hemoglobinuria, Paroxysmal studies →

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 331 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with ESUS, ETUS, or SSS-CVTUS attending the Urgent TIA and Stroke Prevention Clinic or admitted to University or Victoria Hospital, in London, Ontario, Canada.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General:

  • Participants with embolic ischemic stroke (ESUS), embolic (ETUS) or cerebral venous thrombosis (CVTUS) of undetermined source.

For transient ischemic attack (TIA):

One of the following criteria needs to be fulfilled to be considered as embolic TIA:

  • Focal symptoms suggesting involvement of de cerebral cortex in the middle cerebral artery (MCA) territory (e.g., aphasia, neglect, apraxia, dystextia, anosognosia, isolated leg, arm or hand weakness). Some of these symptoms have been described as associated with subcortical fibers connecting cortical areas as well but, despite this, they are usually related to cortical localizations. Patients with hemianopia will be included only if hemianopia is not the primary symptom or an isolated symptom.
  • Rapidly resolving hemispheric symptoms. This concept comprises two components: (a) sudden onset hemispheric syndrome: sudden onset of symptoms and signs implicating extensive ischemia in the internal carotid artery (ICA) or MCA territories, including hemiparesis, hemianopia, conjugate eye deviation, other cortical signs, or altered consciousness; and (b) spectacular shrinking deficit: improvement within 24 hours (approximately).
  • Symptoms involving more than one vascular territory within a single hemisphere (e.g. left sided weakness + left homonymous hemianopia) or both (e.g., left sided weakness and aphasia in a right-handed patient).
  • Simultaneous embolization to other organs (e.g., bowel, spleen, liver, kidneys, toes).
  • Transient monocular blindness (amaurosis fugax) with no evidence of giant cell arteritis (e.g., normal erythrocyte sedimentation rate).
  • No definite cortical symptoms but neuroimaging evidence of prior (chronic) typical infarct (wedge shaped, involving the cerebral cortex).

All of the following criteria must be fulfilled to be considered as TIA of undetermined source:

  • No neuroimaging evidence of an acute brain infarct within the brain region(s) responsible for the presenting symptoms.
  • Absence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the area of ischemia.
  • No major-risk cardioembolic source of embolism.
  • No other specific cause of stroke identified (e.g., arteritis, dissection, migraine, vasospasm, or drug abuse).
  • No persistent neurological focal symptoms at the time of neurological examination. The presence of persistent neurological focal symptoms in the absence of a visible brain infarct on DWI MRI will be regarded as a "clinically confirmed stroke with negative DWI MRI".

Exclusion criteria

Exclusion Criteria:

General:

  • Inability to provide

For stroke patients:

  • Evidence of >50% stenosis of the internal carotid artery (ICA) or MCA ipsilateral to the qualifying ischemic stroke on neurovascular imaging studies.
  • Ischemic stroke involving deep structures and measuring \< 15 mm on diffusion-weighted (DWI) magnetic resonance imaging (MRI). Cortical strokes measuring \<15 mm will qualify to be included in the study.
  • Evidence of a cause explaining the stroke (e.g. hypercoagulable state or any other major source of cardiac embolism).

For patients:

  • Patients no fulfilling the criteria for ETUS.

For cerebral venous thrombosis patients:

  • Subjects without involvement of the superior sagittal sinus (SSS)
  • Subjects with an evident cause explaining the thrombosis (e.g., thrombophilia)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ESUS/ETUS

    Patients with embolic ischemic stroke or transient ischemic attack of undetermined source

  • SSS-CVTUS

    Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source

06

What researchers measure

Primary outcomes

  1. Frequency of PNH in ESUS/ETUS/SSS-CVTUS

    Percentage of patients with flow-cytometry-confirmed PNH

    Time frame: At recruitment

Secondary outcomes

  1. Frequency of PNH in ESUS/ETUS

    Percentage of ESUS/ETUS patients with flow-cytometry-confirmed PNH

    Time frame: At recruitment

  2. Frequency of PNH in SSS-CVT

    Percentage of SSS-CVTUS patients with flow-cytometry-confirmed PNH

    Time frame: At recruitment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03329365
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 1, 2018
Primary completion
Mar 29, 2023
Completion
Mar 29, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Luciano A Sposato, MD
principal investigator · London Health Sciences Center, Western University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion